The Experts below are selected from a list of 86991 Experts worldwide ranked by ideXlab platform

Elham Khanafshar - One of the best experts on this subject based on the ideXlab platform.

  • Papillary Thyroid Carcinoma Variants
    Head and neck pathology, 2011
    Co-Authors: Ricardo V. Lloyd, Darya Buehler, Elham Khanafshar
    Abstract:

    Papillary Thyroid Carcinomas are the most common Thyroid cancers and constitute more than 70% of Thyroid malignancies. The most common etiologic factor is radiation, but genetic susceptibility and other factors also contribute to the development of papillary Thyroid Carcinoma. The most common variants include conventional, follicular variant and tall cell variant. However, many other uncommon variants have been described including oncocytic, columnar cell, diffuse sclerosing and solid forms. Immunohistochemical staining with TTF-1 and thyroglobulin is very useful in confirming the diagnosis of papillary Thyroid Carcinoma especially in metastatic sites. Markers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary Thyroid Carcinomas from follicular adenomas. Molecular studies have shown that the BRAF V600E mutation is found mainly in papillary and anaplastic Thyroid Carcinomas. Other molecular markers such as HMGA2 and insulin-like growth factor II mRNA binding protein 3 have been used recently as molecular tests to separate papillary Thyroid Carcinoma and its variants from follicular adenomas and other benign Thyroid nodules.

  • The spectrum of papillary Thyroid Carcinoma variants.
    Advances in anatomic pathology, 2011
    Co-Authors: Elham Khanafshar, Ricardo V. Lloyd
    Abstract:

    Papillary Thyroid Carcinoma is the most common type of Thyroid malignancy. The diagnostic features of these tumors include characteristic nuclear cytology. However, many variants have been reported with different morphology and molecular profiles. Although the vast majority of papillary Thyroid Carcinomas have an excellent prognosis, some variants of papillary Thyroid Carcinoma can have a more aggressive course. With this increased attention to papillary Thyroid Carcinoma variants has come the need to sort out which variants are clinically important and should be recognized by practicing pathologists. The main objectives of this review article are to (1) summarize the gross and histopathologic features of papillary Thyroid Carcinoma; (2) provide an overview of the subtypes of papillary Thyroid Carcinoma and their prognosis; (3) discuss established and emerging data on the immunohistochemical findings that are helpful in differential diagnosis; and (4) summarize molecular findings and pathogenesis of these lesions.

Ricardo V. Lloyd - One of the best experts on this subject based on the ideXlab platform.

  • Papillary Thyroid Carcinoma Variants
    Head and neck pathology, 2011
    Co-Authors: Ricardo V. Lloyd, Darya Buehler, Elham Khanafshar
    Abstract:

    Papillary Thyroid Carcinomas are the most common Thyroid cancers and constitute more than 70% of Thyroid malignancies. The most common etiologic factor is radiation, but genetic susceptibility and other factors also contribute to the development of papillary Thyroid Carcinoma. The most common variants include conventional, follicular variant and tall cell variant. However, many other uncommon variants have been described including oncocytic, columnar cell, diffuse sclerosing and solid forms. Immunohistochemical staining with TTF-1 and thyroglobulin is very useful in confirming the diagnosis of papillary Thyroid Carcinoma especially in metastatic sites. Markers such as HBME-1 and CITED1 can assist in separating some difficult cases of follicular variants of papillary Thyroid Carcinomas from follicular adenomas. Molecular studies have shown that the BRAF V600E mutation is found mainly in papillary and anaplastic Thyroid Carcinomas. Other molecular markers such as HMGA2 and insulin-like growth factor II mRNA binding protein 3 have been used recently as molecular tests to separate papillary Thyroid Carcinoma and its variants from follicular adenomas and other benign Thyroid nodules.

  • The spectrum of papillary Thyroid Carcinoma variants.
    Advances in anatomic pathology, 2011
    Co-Authors: Elham Khanafshar, Ricardo V. Lloyd
    Abstract:

    Papillary Thyroid Carcinoma is the most common type of Thyroid malignancy. The diagnostic features of these tumors include characteristic nuclear cytology. However, many variants have been reported with different morphology and molecular profiles. Although the vast majority of papillary Thyroid Carcinomas have an excellent prognosis, some variants of papillary Thyroid Carcinoma can have a more aggressive course. With this increased attention to papillary Thyroid Carcinoma variants has come the need to sort out which variants are clinically important and should be recognized by practicing pathologists. The main objectives of this review article are to (1) summarize the gross and histopathologic features of papillary Thyroid Carcinoma; (2) provide an overview of the subtypes of papillary Thyroid Carcinoma and their prognosis; (3) discuss established and emerging data on the immunohistochemical findings that are helpful in differential diagnosis; and (4) summarize molecular findings and pathogenesis of these lesions.

Robert I Haddad - One of the best experts on this subject based on the ideXlab platform.

  • nccn guidelines insights Thyroid Carcinoma version 2 2018
    Journal of The National Comprehensive Cancer Network, 2018
    Co-Authors: Robert I Haddad, Paxton V Dickson, Quanyang Duh, Hormoz Ehya, Christian Nasr, Lindsay Bischoff, Naifa L Busaidy, David Byrd, Glenda G Callender, Whitney S Goldner
    Abstract:

    The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of Thyroid Carcinoma, including papillary, follicular, Hurthle cell, medullary, and anaplastic Carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated Thyroid Carcinoma, implications of the new pathologic diagnosis of noninvasive follicular Thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic Thyroid Carcinoma.

  • Thyroid Carcinoma version 2 2014
    Journal of The National Comprehensive Cancer Network, 2014
    Co-Authors: Michael R Tuttle, Robert I Haddad, Douglas W Ball, David R Byrd, Paxton V Dickson, Quanyang Duh, Hormoz Ehya, Megan R Haymart, Carl K Hoh, Jason P Hunt
    Abstract:

    These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat Thyroid Carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated Thyroid Carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary Thyroid Carcinoma. Other kinase inhibitors may be considered for select patients with either type of Thyroid Carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Jason P Hunt - One of the best experts on this subject based on the ideXlab platform.

  • Thyroid Carcinoma version 2 2014
    Journal of The National Comprehensive Cancer Network, 2014
    Co-Authors: Michael R Tuttle, Robert I Haddad, Douglas W Ball, David R Byrd, Paxton V Dickson, Quanyang Duh, Hormoz Ehya, Megan R Haymart, Carl K Hoh, Jason P Hunt
    Abstract:

    These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat Thyroid Carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated Thyroid Carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary Thyroid Carcinoma. Other kinase inhibitors may be considered for select patients with either type of Thyroid Carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.

Quanyang Duh - One of the best experts on this subject based on the ideXlab platform.

  • nccn guidelines insights Thyroid Carcinoma version 2 2018
    Journal of The National Comprehensive Cancer Network, 2018
    Co-Authors: Robert I Haddad, Paxton V Dickson, Quanyang Duh, Hormoz Ehya, Christian Nasr, Lindsay Bischoff, Naifa L Busaidy, David Byrd, Glenda G Callender, Whitney S Goldner
    Abstract:

    The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of Thyroid Carcinoma, including papillary, follicular, Hurthle cell, medullary, and anaplastic Carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated Thyroid Carcinoma, implications of the new pathologic diagnosis of noninvasive follicular Thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic Thyroid Carcinoma.

  • Thyroid Carcinoma version 2 2014
    Journal of The National Comprehensive Cancer Network, 2014
    Co-Authors: Michael R Tuttle, Robert I Haddad, Douglas W Ball, David R Byrd, Paxton V Dickson, Quanyang Duh, Hormoz Ehya, Megan R Haymart, Carl K Hoh, Jason P Hunt
    Abstract:

    These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat Thyroid Carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated Thyroid Carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary Thyroid Carcinoma. Other kinase inhibitors may be considered for select patients with either type of Thyroid Carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.